EXAI vs. CABA, KYTX, NVAX, HUMA, PRME, VALN, PROK, HLVX, ALEC, and ALLO
Should you be buying Exscientia stock or one of its competitors? The main competitors of Exscientia include Cabaletta Bio (CABA), Kyverna Therapeutics (KYTX), Novavax (NVAX), Humacyte (HUMA), Prime Medicine (PRME), Valneva (VALN), ProKidney (PROK), HilleVax (HLVX), Alector (ALEC), and Allogene Therapeutics (ALLO). These companies are all part of the "biological products, except diagnostic" industry.
Cabaletta Bio (NASDAQ:CABA) and Exscientia (NASDAQ:EXAI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking.
Cabaletta Bio received 66 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 69.44% of users gave Cabaletta Bio an outperform vote while only 36.00% of users gave Exscientia an outperform vote.
Cabaletta Bio has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Exscientia has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
In the previous week, Exscientia had 5 more articles in the media than Cabaletta Bio. MarketBeat recorded 13 mentions for Exscientia and 8 mentions for Cabaletta Bio. Exscientia's average media sentiment score of 0.97 beat Cabaletta Bio's score of 0.08 indicating that Cabaletta Bio is being referred to more favorably in the media.
41.6% of Exscientia shares are owned by institutional investors. 9.9% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cabaletta Bio has higher earnings, but lower revenue than Exscientia. Cabaletta Bio is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.
Cabaletta Bio has a net margin of 0.00% compared to Cabaletta Bio's net margin of -737.10%. Cabaletta Bio's return on equity of -36.44% beat Exscientia's return on equity.
Cabaletta Bio presently has a consensus target price of $34.33, indicating a potential upside of 200.64%. Exscientia has a consensus target price of $9.75, indicating a potential upside of 96.57%. Given Exscientia's stronger consensus rating and higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than Exscientia.
Summary
Cabaletta Bio beats Exscientia on 10 of the 17 factors compared between the two stocks.
Get Exscientia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exscientia Competitors List
Related Companies and Tools
